Stefano Cascinu

List of Publications by Year
in descending order

Version: 2024-02-01

705 papers	20,804 citations	13854 67 h-index	20943 115 g-index
728 all docs	728 docs citations	728 times ranked	25210 citing authors

#	Article	IF	Citations
1	Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index. Journal of Gastrointestinal Cancer, 2022, 53, 289-298.	0.6	6
2	Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery. Hpb, 2022, 24, 244-254.	0.1	4
3	The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer: A systematic review and meta-analysis of randomized trials. Critical Reviews in Oncology/Hematology, 2022, 173, 103674.	2.0	17
4	Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study.. Journal of Clinical Oncology, 2022, 40, 4069-4069.	0.8	5
5	Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and Clinical Outcomes in MSI-H population: The PROSECCO Study.. Journal of Clinical Oncology, 2022, 40, e16068-e16068.	0.8	0
6	Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus. Tumori, 2021, 107, 550-555.	0.6	5
7	The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 554-560.	3.3	10
8	Tumor Response and Symptom Palliation from RAINBOW , a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. Oncologist, 2021, 26, e414-e424.	1.9	4
9	Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma: Ready for Prime Time?. Gastroenterology, 2021, 160, 1423-1424.	0.6	1
10	Potential acceptance of COVID-19 vaccine in rheumatological patients: a monocentric comparative survey. Annals of the Rheumatic Diseases, 2021, 80, 816-817.	0.5	30
11	Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma?. Medical Oncology, 2021, 38, 17.	1.2	2
12	The Prognostic Value of the New Combined Hemo-Eosinophil Inflammation Index (HEI Index): A Multicenter Analysis of Anal Cancer Patients Treated with Concurrent Chemo-Radiation. Cancers, 2021, 13, 671.	1.7	7
13	Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort. ESMO Open, 2021, 6, 100032.	2.0	19
14	Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison. Targeted Oncology, 2021, 16, 249-254.	1.7	18
15	Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). Cancers, 2021, 13, 1304.	1.7	2
16	Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3665-3671.	1.2	12
17	Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer â€“ A GISCAD phase II randomized trial. European Journal of Cancer, 2021, 148, 422-429.	1.3	8
18	Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice. Frontiers in Oncology, 2021, 11, 637823.	1.3	8

#	Article	IF	Citations
19	A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index. Journal of Gastrointestinal Cancer, 2021, , 1.	0.6	0
20	Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib. Hepatology Research, 2021, 51, 796-802.	1.8	4
21	Laparoscopic Surgery for Intrahepatic Cholangiocarcinoma: A Focus on Oncological Outcomes. Journal of Clinical Medicine, 2021, 10, 2828.	1.0	11
22	Impact of Aspirin on clinical outcome in advanced HCC patients receiving sorafenib and regorafenib. Hpb, 2021, 23, 915-920.	0.1	14
23	Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib. Liver International, 2021, 41, 2997-3008.	1.9	18
24	Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma. ESMO Open, 2021, 6, 100190.	2.0	12
25	Lenvatinib versus Sorafenib as firstâ€line treatment in hepatocellular carcinoma: A multiâ€institutional matched caseâ€control study. Hepatology Research, 2021, 51, 1229-1241.	1.8	33
26	Prediction of Early Distant Recurrence in Upfront Resectable Pancreatic Adenocarcinoma: A Multidisciplinary, Machine Learning-Based Approach. Cancers, 2021, 13, 4938.	1.7	16
27	Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): aÂmulticenter survey. ESMO Open, 2021, 6, 100238.	2.0	12
28	Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. ESMO Open, 2021, 6, 100330.	2.0	25
29	Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy. Cancer Management and Research, 2021, Volume 13, 9379-9389.	0.9	31
30	Oral anticancer therapy project: Clinical utility of a specific home care nursing programme on behalf of Italian Association of Medical Oncology (AIOM). Journal of Clinical Nursing, 2020, 29, 119-129.	1.4	3
31	Treating cancer with immunotherapy in HIV-positive patients: A challenging reality. Critical Reviews in Oncology/Hematology, 2020, 145, 102836.	2.0	9
32	The prognostic nutritional index predicts survival and response to firstâ€line chemotherapy in advanced biliary cancer. Liver International, 2020, 40, 704-711.	1.9	42
33	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. Targeted Oncology, 2020, 15, 773-785.	1.7	12
34	Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy. Cancer Biology and Therapy, 2020, 21, 891-898.	1.5	14
35	Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approach. Expert Opinion on Therapeutic Targets, 2020, 24, 937-943.	1.5	10
36	Validation and refinement of PROSASH model using the neutrophilâ€toâ€lymphocyte ratio in patients with HCC receiving sorafenib. Liver Cancer International, 2020, 1, 6-11.	0.2	0

#	Article	IF	Citations
37	The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference. International Journal of Colorectal Disease, 2020, 35, 1513-1527.	1.0	7
38	Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. Clinical Cancer Research, 2020, 26, 4485-4493.	3.2	13
39	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. PLoS ONE, 2020, 15, e0232449.	1.1	29
40	Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. Cancers, 2020, 12, 1153.	1.7	4
41	Personalized Riskâ€“Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak. Oncologist, 2020, 25, e1013-e1020.	1.9	28
42	From CENTRAL to SENTRAL (SErum aNgiogenesis cenTRAL): Circulating Predictive Biomarkers to Anti-VEGFR Therapy. Cancers, 2020, 12, 1330.	1.7	7
43	Lenvatinib and pembrolizumab in advanced gastric cancer. Lancet Oncology, The, 2020, 21, 1004-1005.	5.1	9
44	Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib. Medicine (United States), 2020, 99, e19958.	0.4	13
45	Is There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis. Clinical Colorectal Cancer, 2020, 19, 82-90.e9.	1.0	6
46	Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial. Therapeutic Advances in Medical Oncology, 2020, 12, 175883591989028.	1.4	6
47	Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. Oncologist, 2020, 25, 481-487.	1.9	77
48	Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study. European Journal of Cancer, 2020, 127, 150-157.	1.3	22
49	Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study. Targeted Oncology, 2020, 15, 115-126.	1.7	15
50	Imaging and clinical correlates with regorafenib in metastatic colorectal cancer. Cancer Treatment Reviews, 2020, 86, 102020.	3.4	9
51	The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis. Cancers, 2020, 12, 1022.	1.7	16
52	Immunohistochemical mismatch repair proteins expression as a tool to predict the melanoma immunotherapy response. Molecular and Clinical Oncology, 2020, 12, 3-8.	0.4	9
53	Breast ultrasonography (BU) in the screening protocol for women at hereditaryâ€familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories?. International Journal of Cancer, 2019, 144, 1001-1009.	2.3	16
54	First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis. Clinical Breast Cancer, 2019, 19, e701-e716.	1.1	10

#	Article	IF	Citations
55	Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. Clinical Genitourinary Cancer, 2019, 17, e903-e908.	0.9	30
56	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the â€˜BRAF BeCoolâ€™ study. European Journal of Cancer, 2019, 118, 121-130.	1.3	51
57	Is there an optimal choice in refractory colorectal cancer? A network meta-analysis. Annals of Oncology, 2019, 30, iv14.	0.6	1
58	ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. Cancers, 2019, 11, 1023.	1.7	23
59	The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy. European Journal of Cancer, 2019, 117, 84-90.	1.3	21
60	Immune-inflammatory and clinicopathologic prognostic factors in a Western cohort of resected gastric cancers (GCs). Annals of Oncology, 2019, 30, iv75.	0.6	1
61	Characterization of mismatch repair deficiency in biliary tract cancer. Annals of Oncology, 2019, 30, iv76.	0.6	0
62	A new prognostic score for biliary tract cancer: a multicenter experience. Annals of Oncology, 2019, 30, iv92.	0.6	0
63	Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: results of INNOVATE study. Annals of Oncology, 2019, 30, iv113.	0.6	0
64	BRAF-Mutated Colorectal Cancer: Clinical and Molecular Insights. International Journal of Molecular Sciences, 2019, 20, 5369.	1.8	88
65	Sorafenib in patients with hepatocellular carcinoma: 10 years of real life. Annals of Oncology, 2019, 30, iv57.	0.6	0
66	Gastric cancer: Translating novels concepts into clinical practice. Cancer Treatment Reviews, 2019, 79, 101889.	3.4	60
67	A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. Cancer Immunology, Immunotherapy, 2019, 68, 1547-1559.	2.0	32
68	Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. Gastrointestinal Tumors, 2019, 6, 92-107.	0.3	22
69	Role of evaluating tumorâ€‘infiltrating lymphocytes, programmed deathâ€‘1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma. International Journal of Oncology, 2019, 55, 1157-1164.	1.4	13
70	<p>Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50		
71	Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials . OncoTargets and Therapy, 2019, Volume 12, 2981-2988.	1.0	26
72	Is there a role for chemotherapy after local relapse in highâ€grade osteosarcoma?. Pediatric Blood and Cancer, 2019, 66, e27792.	0.8	19

#	Article	IF	Citations
73	Clinical impact of different exosomesâ€™ protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy. PLoS ONE, 2019, 14, e0215990.	1.1	24
74	Impact of laterality and mucinous histology on relapse-free and overall survival in a registry-based colon cancer series. Scientific Reports, 2019, 9, 3668.	1.6	7
75	Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. Clinical Cancer Research, 2019, 25, 3954-3961.	3.2	67
76	The Italian Rare Pancreatic Exocrine Cancer Initiative. Tumori, 2019, 105, 353-358.	0.6	7
77	Are we ready to describe response or progression to immunotherapy in lung cancer?. Critical Reviews in Oncology/Hematology, 2019, 138, 112-119.	2.0	10
78	Role of SIRT-3, p-mTOR and HIF-1Î± in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin. International Journal of Molecular Sciences, 2019, 20, 1503.	1.8	24
79	The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials. European Journal of Cancer, 2019, 111, 1-7.	1.3	12
80	Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer. Scientific Reports, 2019, 9, 1788.	1.6	57
81	Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies. Cancers, 2019, 11, 193.	1.7	12
82	Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort. Gastrointestinal Tumors, 2019, 6, 71-80.	0.3	4
83	Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy . Cancer Management and Research, 2019, Volume 11, 9563-9569.	0.9	17
84	High levels of Notch intracellular cleaved domain are associated with stemness and reduced bevacizumab efficacy in patients with advanced colon cancer. Oncology Reports, 2019, 42, 2750-2758.	1.2	7
85	Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. Oncologist, 2019, 24, 185-192.	1.9	89
86	Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. Journal of Cancer Research and Clinical Oncology, 2019, 145, 821-828.	1.2	4
87	Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. Breast Cancer, 2019, 26, 520-523.	1.3	6
88	Oligometastatic gastric cancer: An emerging clinical entity with distinct therapeutic implications. European Journal of Surgical Oncology, 2019, 45, 1479-1482.	0.5	10
89	Atrial fibrillation in patients with active malignancy and use of anticoagulants: Under-prescription but no adverse impact on all-cause mortality. European Journal of Internal Medicine, 2019, 59, 27-33.	1.0	31
90	Occult breast cancer: the uncommon presentation of a common disease. Chinese Clinical Oncology, 2019, 8, S10-S10.	0.4	4

#	Article	IF	Citations
91	Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. International Journal of Surgery, 2018, 51, 120-127.	1.1	106
92	An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study. Expert Review of Pharmacoeconomics and Outcomes Research, 2018, 18, 435-446.	0.7	9
93	Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives. Critical Reviews in Oncology/Hematology, 2018, 123, 149-161.	2.0	50
94	Stevensâ€"Johnson syndrome during nivolumab treatment of NSCLC. Annals of Oncology, 2018, 29, 283-284.	0.6	50
95	Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 814-824.	1.4	18
96	Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History. Clinical Breast Cancer, 2018, 18, e15-e24.	1.1	18
97	The role of primary tumour location in the recurrence rate of metachronous metastasis of colon cancer. Annals of Oncology, 2018, 29, viii196.	0.6	0
98	Correlation between immuno-related adverse events (IRAEs) occurrence and clinical outcome in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: IRAENE trial, an Italian multi-institutional retrospective study. Annals of Oncology, 2018, 29, viii316.	0.6	2
99	General and dedicated cancer emergency room: Clinical and financial implications. Annals of Oncology, 2018, 29, viii623.	0.6	0
100	ERBB2 and PI3KCA mutations in endocrine resistant breast cancer (BC). Annals of Oncology, 2018, 29, vi30.	0.6	0
101	The DISTINCTIVE study: A biologically enriched phase II study of seconD-line folfiri/aflIbercept in proSpecTIvely stratified, anti-EGFR resistaNt, metastatic coloreCTal cancer patIents with RAS Validated wild typE status - Trial in progress. Annals of Oncology, 2018, 29, v82.	0.6	3
102	First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better?. Annals of Oncology, 2018, 29, viii110.	0.6	0
103	A novel immune-inflammatory score to predict survival in patients (pts) with advanced biliary tract cancer (ABTC) receiving first-line chemotherapy (1-line cht). Annals of Oncology, 2018, 29, viii263.	0.6	0
104	A novel electronic tool to implement palliative sedation (PS) in a department of oncologic medicine. Annals of Oncology, 2018, 29, viii554.	0.6	0
105	The role of adjuvant therapy in resectable SBA: A different clinicians attitude with a relevant impact on outcome. Annals of Oncology, 2018, 29, viii264.	0.6	0
106	Role of evaluating tumor infiltrating lymphocytes, programmed death-ligand 1 and mismatch-repair proteins expression in malignant mesothelioma. Annals of Oncology, 2018, 29, viii641-viii642.	0.6	0
107	To resect or not to resect: The hamletic dilemma of primary tumor resection in patients with asymptomatic stage IV colorectal cancer. Critical Reviews in Oncology/Hematology, 2018, 132, 154-160.	2.0	5
108	Lenvatinib as a therapy for unresectable hepatocellular carcinoma. Expert Review of Anticancer Therapy, 2018, 18, 1069-1076.	1.1	25

#	Article	IF	Citations
109	P 53 abnormal expression might influence global outcome through EGFR modulation in RAS/BRAF wild type metastatic colorectal cancer patients receiving later-line irinotecan cetuximab. Annals of Oncology, 2018, 29, v58-v59.	0.6	0
110	Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus. BioMed Research International, 2018, 2018, 1-8.	0.9	9
111	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. Tumori, 2018, 104, 476-479.	0.6	14
112	Italian Nivolumab Expanded Access Program inÂNonsquamous Nonâ€“Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. Journal of Thoracic Oncology, 2018, 13, 1146-1155.	0.5	77
113	Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors. Pancreas, 2018, 47, 759-771.	0.5	29
114	Beyond the Beyond: A Case of an Extraordinary Response to Multiple Lines of Therapy in a de novo Metastatic HER2-Negative Gastric Cancer Patient. Gastrointestinal Tumors, 2018, 5, 14-20.	0.3	6
115	Late Gastrointestinal Toxicity During Nivolumab Therapy in Nonâ€“Small CellÂLung Cancer: A Rare Case of Inflammatory Bowel Disease. Journal of Thoracic Oncology, 2018, 13, e152-e153.	0.5	2
116	Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. Cancer Biology and Therapy, 2018, 19, 879-886.	1.5	22
117	The prognostic role of hemoglobin levels in patients undergoing concurrent chemo-radiation for anal cancer. Radiation Oncology, 2018, 13, 83.	1.2	23
118	Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. Cancer Management and Research, 2018, Volume 10, 91-103.	0.9	53
119	Personalized management of elderly patients with rectal cancer: Expert recommendations of the European Society of Surgical Oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons Commission on Cancer. European Journal of Surgical Oncology, 2018, 44, 1685-1702.	0.5	100
120	Dabrafenibâ€“trametinib combination in â€˜field-practiceâ€™: an Italian experience. Future Oncology, 2018, 14, 2045-2052.	1.1	3
121	Anti-EGFR therapy in oesophagogastric cancer: precise but not enough. Annals of Oncology, 2018, 29, 1884-1885.	0.6	3
122	Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. Gastric Cancer, 2017, 20, 156-163.	2.7	62
123	Anal cancer: from an orphan disease to a curable malignancy?. Lancet Oncology, The, 2017, 18, 415-416.	5.1	1
124	A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. BMC Cancer, 2017, 17, 137.	1.1	47
125	Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. Scientific Reports, 2017, 7, 42499.	1.6	30
126	Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Critical Reviews in Oncology/Hematology, 2017, 111, 152-165.	2.0	28

#	Article	IF	Citations
127	Emerging antibodies for the treatment of pancreatic cancer. Expert Opinion on Emerging Drugs, 2017, 22, 39-51.	1.0	9
128	Advanced gastric cancer: is there an optimal chemotherapy regimen?. Expert Review of Quality of Life in Cancer Care, 2017, 2, 123-132.	0.6	0
129	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. British Journal of Cancer, 2017, 117, 315-321.	2.9	19
130	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. Cancer Medicine, 2017, 6, 1493-1499.	1.3	11
131	Ang-2 polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib. Digestive and Liver Disease, 2017, 49, e19.	0.4	1
132	Validation of a simple scoring system to predict sorafenib effectiveness in patients with hepatocellular carcinoma. Digestive and Liver Disease, 2017, 49, e42.	0.4	0
133	Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. Breast Journal, 2017, 23, 610-611.	0.4	7
134	A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study). Clinical Colorectal Cancer, 2017, 16, 410-415.e1.	1.0	7
135	Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis. Scientific Reports, 2017, 7, 45703.	1.6	22
136	Borderline resectable pancreatic cancer: More than an anatomical concept. Digestive and Liver Disease, 2017, 49, 223-226.	0.4	15
137	Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Targeted Oncology, 2017, 12, 97-109.	1.7	56
138	Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. European Journal of Cancer, 2017, 86, 106-114.	1.3	76
139	Trifluridine tipiracil (TAS 102) in patients with stage IV pretreated colorectal neoplasm: an experience from Rimini City Hospital. Annals of Oncology, 2017, 28, iii117-iii118.	0.6	1
140	Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer?. ESMO Open, 2017, 2, e000206.	2.0	37
141	First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 117, 1099-1104.	2.9	11
142	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. European Journal of Cancer, 2017, 83, 106-115.	1.3	25
143	Quality of Life and Anxious-depressive Symptoms in Cancer Patients Undergoing Mindfulness-based Interventions: Feasibility and Preliminary Outcomes on Prospective Single-centre Case-control Study (MIND4ME St.). European Psychiatry, 2017, 41, S252-S252.	0.1	0
144	Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. Targeted Oncology, 2017, 12, 795-803.	1.7	23

#	Article	IF	Citations
145	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. European Journal of Cancer, 2017, 82, 16-24.	1.3	40
146	Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients. European Journal of Surgical Oncology, 2017, 43, 613-618.	0.5	49
147	The Role of Aspirin as Antitumoral Agent for Heavily Pretreated Patients With Metastatic Colorectal Cancer Receiving Capecitabine Monotherapy. Clinical Colorectal Cancer, 2017, 16, 38-43.	1.0	18
148	Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. Annals of Oncology, 2017, 28, vi38-vi39.	0.6	0
149	Sidedness influences prognosis in colon cancer patients receiving an adjuvant therapy. A GISCAD analysis from three randomized trials including 5234 patients. Annals of Oncology, 2017, 28, vi5.	0.6	3
150	The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild type colorectal cancer patients receiving irinotecan/cetuximab. Annals of Oncology, 2017, 28, vi9-vi10.	0.6	0
151	The prognostic impact of sidedness across all stages during the last 20 years: the â€œModena Cancer Registryâ€•experience. Annals of Oncology, 2017, 28, vi10.	0.6	0
152	Outcome and prognostic factors after resection of liver metastases in patients with colorectal cancer. Annals of Oncology, 2017, 28, vi13-vi14.	0.6	2
153	Somatostatin analogs: is one better than other?. Therapeutic Advances in Medical Oncology, 2017, 9, 817-819.	1.4	2
154	Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapy. Oncotarget, 2017, 8, 23871-23879.	0.8	36
155	Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?. International Journal of Molecular Sciences, 2017, 18, 85.	1.8	25
156	Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. American Journal of Case Reports, 2017, 18, 208-211.	0.3	11
157	Position Paper of the Italian Association of Medical Oncology on Early Palliative Care in Oncology Practice (Simultaneous Care). Tumori, 2017, 103, 9-14.	0.6	26
158	The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation. Oncotarget, 2017, 8, 9144-9154.	0.8	26
159	Family history of pancreatic cancer in BRCA1/2 testing criteria. Annals of Oncology, 2017, 28, vi46.	0.6	0
160	Small bowel adenocarcinoma (SBA) is a rare and heterogeneous disease: results of a retrospective analysis. Annals of Oncology, 2017, 28, vi50-vi51.	0.6	0
161	GD2 expression in breast cancer. Oncotarget, 2017, 8, 31592-31600.	0.8	38
162	BRAF, NRAS and C-KIT Advanced Melanoma: Clinico-pathological Features, Targeted-Therapy Strategies and Survival. Anticancer Research, 2017, 37, 7043-7048.	0.5	33

#	Article	IF	Citations
163	Heavily calcified gastrointestinal stromal tumors: Pathophysiology and implications of a rare clinicopathologic entity. World Journal of Gastrointestinal Oncology, 2017, 9, 135.	0.8	12
164	Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the phase 3b CONSIGN trial who had progression-free survival (PFS) >4 months (m). Annals of Oncology, 2016, 27, iv47.	0.6	1
165	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors (PNETs). Annals of Oncology, 2016, 27, vi145.	0.6	0
166	Emerging Immunotargets in Metastatic Renal Cell Carcinoma. Current Drug Targets, 2016, 17, 771-776.	1.0	20
167	BRCA mutations and IGF-R1 expression in modulating sensitivity to Trastuzumab in patients with HER2-positive breast cancer. Annals of Oncology, 2016, 27, iv65.	0.6	1
168	Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue. Oncotarget, 2016, 7, 58649-58658.	0.8	76
169	Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New. BioMed Research International, 2016, 2016, 1-7.	0.9	45
170	Clinical and Pathologic Predictors of Clinical Outcome of Malignant Pleural Mesothelioma. Tumori, 2016, 102, 190-195.	0.6	9
171	Early Integration of Palliative Care in Oncology Practice: Results of the Italian Association of Medical Oncology (AIOM) Survey. Journal of Cancer, 2016, 7, 1968-1978.	1.2	15
172	Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical Trials. PLoS ONE, 2016, 11, e0152079.	1.1	38
173	Clinical and pathological features of rare histological exocrine pancreatic cancers (PCs): a retrospective multicentric analysis. Annals of Oncology, 2016, 27, iv21.	0.6	0
174	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors (PNETs). Annals of Oncology, 2016, 27, iv22.	0.6	0
175	Mismatch repair protein expression and inflammation in human pancreatic cancer. Annals of Oncology, 2016, 27, iv23.	0.6	0
176	Pre and post anti Her-2 therapy era: a mono-institutional analysis of the outcome in patients with residual disease after neoadjuvant therapy for Her-2 positive locally advanced breast cancer. Annals of Oncology, 2016, 27, iv73.	0.6	0
177	Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. Annals of Oncology, 2016, 27, iv75.	0.6	0
178	Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?. European Journal of Surgical Oncology, 2016, 42, 1533-1539.	0.5	104
179	Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report. BMC Research Notes, 2016, 9, 497.	0.6	11
180	Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. Annals of Oncology, 2016, 27, iv69.	0.6	1

#	Article	IF	Citations
181	Early onset of hyperthension and serum electrolite changes as potential predictive factors of activity in advanced HCC treated with sorafeinb: Results from a retrospective analysis of HCC-AVR group. Digestive and Liver Disease, 2016, 48, e36.	0.4	0
182	ENOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS Study. Digestive and Liver Disease, 2016, 48, e23.	0.4	1
183	Reply to O. Corli et al and M. Lucchesi et al. Journal of Clinical Oncology, 2016, 34, 3580-3581.	0.8	0
184	Final results and outcomes by prior bevacizumab exposure, skin toxicity,Âand hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. European Journal of Cancer, 2016, 68, 51-59.	1.3	56
185	Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer. Oncology Reports, 2016, 36, 755-762.	1.2	4
186	Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC). Targeted Oncology, 2016, 11, 489-500.	1.7	22
187	The evolving role of microsatellite instability in colorectal cancer: A review. Cancer Treatment Reviews, 2016, 51, 19-26.	3.4	207
188	Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. Scientific Reports, 2016, 6, 25195.	1.6	25
189	The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. Scientific Reports, 2016, 6, 24136.	1.6	22
190	Circulating pro-angiogenic markers in patients receiving first-line FOLFIRI + bevacizumab. The SENTRAL (Serum angiogenesis-cENTRAL) pre-planned analysis of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL trial (ColorEctalvastiNTRiAlLdh). Annals of Oncology, 2016, 27, vi178.	0.6	0
191	Multicentric prospective study of validation of angiogenesis polymorphisms in HCC patients treated with sorafenib. INNOVATE study. Annals of Oncology, 2016, 27, vi239.	0.6	0
192	An Italian cost-effectiveness analysis of paclitaxel albumin (nabÂ®-paclitaxel) + gemcitabine vs gemcibatine alone for metastatic pancreatic cancer patients: The APICE study. Annals of Oncology, 2016, 27, vi358.	0.6	0
193	Regorafenib in previously treated metastatic colorectal cancer (mCRC): Analysis of age subgroups in the open-label phase 3b CONSIGN trial. Annals of Oncology, 2016, 27, iv44.	0.6	0
194	Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. Annals of Oncology, 2016, 27, vi84.	0.6	0
195	BRCA mutations and IGF-R1 expression in modulating sensitivity to trastuzumab in HER2-positive breast cancer. Annals of Oncology, 2016, 27, vi51.	0.6	0
196	Correlation of Stomatitis and Cutaneous Toxicity With Clinical Outcome in Patients With Metastatic Renal-Cell Carcinoma Treated With Everolimus. Clinical Genitourinary Cancer, 2016, 14, 426-431.	0.9	9
197	Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis. Targeted Oncology, 2016, 11, 143-148.	1.7	152
198	Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategyâ€"A literature review. Critical Reviews in Oncology/Hematology, 2016, 98, 264-274.	2.0	26

#	Article	IF	Citations
199	Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain. Journal of Clinical Oncology, 2016, 34, 436-442.	0.8	145
200	Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Critical Reviews in Oncology/Hematology, 2016, 98, 309-324.	2.0	35
201	Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?. Critical Reviews in Oncology/Hematology, 2016, 100, 99-106.	2.0	11
202	Speckle-tracking global longitudinal strain as an early predictor of cardiotoxicity in breast carcinoma. Supportive Care in Cancer, 2016, 24, 3139-45.	1.0	19
203	Hyponatremia in cancer patients: Time for a new approach. Critical Reviews in Oncology/Hematology, 2016, 102, 15-25.	2.0	50
204	Out-of-pocket costs for cancer survivors between 5 and 10Âyears from diagnosis: an Italian population-based study. Supportive Care in Cancer, 2016, 24, 2225-2233.	1.0	17
205	Current Histopathologic and Molecular Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. European Urology, 2016, 69, 186-190.	0.9	18
206	Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1Î±â€"Final results of the ALICE-2 study.. Journal of Clinical Oncology, 2016, 34, 280-280.	0.8	13
207	What Medical Oncologist Residents Think about the Italian Speciality Schools: A Survey of the Italian Association of Medical Oncology (AIOM) on Educational, Clinical and Research Activities. PLoS ONE, 2016, 11, e0159146.	1.1	3
208	Hormonal receptors in lung adenocarcinoma: expression and difference in outcome by sex. Oncotarget, 2016, 7, 82648-82657.	0.8	30
209	Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group. Oncotarget, 2016, 7, 15243-15251.	0.8	26
210	Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. Oncotarget, 2016, 7, 33381-33390.	0.8	11
211	Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy. Oncotarget, 2016, 7, 26916-26924.	0.8	44
212	eNOSpolymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. Oncotarget, 2016, 7, 27988-27999.	0.8	30
213	Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma. Oncotarget, 2016, 7, 37599-37607.	0.8	14
214	Emerging Immunotargets in Bladder Cancer. Current Drug Targets, 2016, 17, 757-770.	1.0	9
215	Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. World Journal of Gastrointestinal Oncology, 2016, 8, 389.	0.8	20
216	Systemic immune-inflammation index to predict the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.. Journal of Clinical Oncology, 2016, 34, 547-547.	0.8	1

#	Article	IF	Citations
217	Gastro-entero-pancreatic neuroendocrine tumors: Is now time for a new approach?. World Journal of Clinical Oncology, 2016, 7, 131.	0.9	1
218	Efficacy of cetuximab immediately after bevacizumab: A phase III multicenter trial comparing two different sequences of cetuximab and FOLFOX in K-Ras WT metastatic colorectal cancer patients refractory FOLFIRI/bevacizumab.. Journal of Clinical Oncology, 2016, 34, 632-632.	0.8	1
219	Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemofractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2016, 34, 507-507.	0.8	7
220	Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT.. Journal of Clinical Oncology, 2016, 34, 519-519.	0.8	4
221	Characterizing tumor responses from RAINBOW, a randomized phase III trial of ramucirumab (RAM) plus paclitaxel (PAC) vs placebo (PBO) plus PAC in patients (pts) with previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, 45-45.	0.8	0
222	Abstract 3401: Impact of VEGF and VEGFR polymorphisms on neuroendocrine tumors of the gastro-entero-pancreatic system (GEPNETs) outcome. , 2016, , .		0
223	2110 Efficacy outcomes by severity of skin toxicity from ASPECCT: Randomized phase 3 study of panitumumab (pmab) versus cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC). European Journal of Cancer, 2015, 51, S366.	1.3	0
224	2143 Regorafenib for previously treated metastatic colorectal cancer (mCRC): Results from 683 Italian patients treated in the open-label phase 3B CONSIGN study. European Journal of Cancer, 2015, 51, S380-S381.	1.3	0
225	2390 LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first line chemotherapy. European Journal of Cancer, 2015, 51, S467.	1.3	0
226	2580 Multigene profiling in incidentally- and clinically detected prostate cancer. European Journal of Cancer, 2015, 51, S504-S505.	1.3	0
227	3092 Systemic immune-inflammation index (SII) in patients with advanced non-small cell lung cancer (nsclc). European Journal of Cancer, 2015, 51, S630.	1.3	1
228	Regorafenib for previously treated metastatic colorectal cancer (mCRC): results from 683 Italian patients treated in the open-label phase IIIB CONSIGN study. Annals of Oncology, 2015, 26, vi37.	0.6	0
229	Secondary breast cancer prevention: it's time to get moving!. Annals of Oncology, 2015, 26, vi147.	0.6	0
230	Mismatch repair protein expression and Hedgehog signalling pathways in human pancreatic cancer. Annals of Oncology, 2015, 26, vi92.	0.6	0
231	P0313 : Correlation between VEGF and VEGF-R polymorphisms, toxicity and clinical outcome in HCC patients receiving sorafenib. Journal of Hepatology, 2015, 62, S426.	1.8	0
232	2603 Complete remission (CR) during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs). European Journal of Cancer, 2015, 51, S512-S513.	1.3	0
233	Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis. SpringerPlus, 2015, 4, 743.	1.2	10
234	BRCA1/2 mutations and hereditary breast cancer: clinical phenotype, type of mutation and founder effect. Annals of Oncology, 2015, 26, vi15.	0.6	0

#	Article	IF	Citations
235	Soft tissue sarcoma after haematological malignancies in childhood/adolescence: a hospital series. Annals of Oncology, 2015, 26, vi30.	0.6	0
236	Role of different toxicity profile on outcome for colorectal cancer patients receiving Regorafenib monotherapy. Annals of Oncology, 2015, 26, vi51.	0.6	0
237	Clinical and pathological predictors of outcome for malignant pleural mesothelioma. Annals of Oncology, 2015, 26, vi89.	0.6	0
238	Risk for developing hyponatraemia in cancer patients treated with targeted therapies: a meta-analysis. Annals of Oncology, 2015, 26, vi135.	0.6	0
239	Evaluation of clinical and pathological features in patients with Lynch Syndrome-related Endometrial Cancer: a single centre experience. Annals of Oncology, 2015, 26, vi34.	0.6	0
240	Osteopontin (OPN) and interleukin-6 (IL-6) as predictive biomarkers in HCC receiving loco-regional treatment: preliminary results. Annals of Oncology, 2015, 26, vi104.	0.6	1
241	Bone metastases (BMs) in patients with advanced non-small cell lung cancer (NSCLC): do they always correlate with poor prognosis?. Annals of Oncology, 2015, 26, vi86.	0.6	0
242	HER family Receptor Expression and Prognosis in Pancreatic Cancer. International Journal of Biological Markers, 2015, 30, 327-332.	0.7	9
243	Patient and Caregiver Needs in Oncology. An Italian Survey. Tumori, 2015, 101, 621-625.	0.6	7
244	Prognostic Value for Incidental Antihypertensive Therapy With Î²-Blockers in Metastatic Colorectal Cancer. Medicine (United States), 2015, 94, e719.	0.4	18
245	The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Oncotarget, 2015, 6, 35087-35094.	0.8	40
246	Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology. OncoTargets and Therapy, 2015, 8, 1149.	1.0	5
247	MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?. Oncotarget, 2015, 6, 23323-23341.	0.8	65
248	New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. Cancer Treatment Reviews, 2015, 41, 614-622.	3.4	19
249	Lgr5 expression, cancer stem cells and pancreatic cancer: results from biological and computational analyses. Future Oncology, 2015, 11, 1037-1045.	1.1	10
250	Small renal masses in the era of personalized medicine: Tumor heterogeneity, growth kinetics, and risk of metastasis. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 303-309.	0.8	16
251	Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. Critical Reviews in Oncology/Hematology, 2015, 96, 81-90.	2.0	64
252	Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. Expert Opinion on Biological Therapy, 2015, 15, 155-162.	1.4	27

#	Article	IF	Citations
253	Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab. Journal of Translational Medicine, 2015, 13, 140.	1.8	6
254	Present and future of personalized medicine in adult genitourinary tumors. Future Oncology, 2015, 11, 1381-1388.	1.1	10
255	Endocrine therapy is not effective in BRCA2 mutated breast cancers even when they express hormonal receptors. Annals of Oncology, 2015, 26, vi11.	0.6	1
256	Impact and prognostic role of single-neucleotide polymorphisms (SNPs) in thymic lesions. Annals of Oncology, 2015, 26, vi79.	0.6	0
257	Advanced non-small cell lung cancer (NSCLC): the prognostic role of systemic Immune-Inflammation Index (SII). Annals of Oncology, 2015, 26, vi74.	0.6	0
258	There is a difference of vitamin D receptor gene (VDR) single-nucleotide polymorphisms (SNPs) frequencies between malignant melanoma patients and healthy volunteers and by sex?. Annals of Oncology, 2015, 26, vi26.	0.6	0
259	2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in Journal of Cancer, 2015, 51, S329.	1.3	3
260	Role of STAT3 pathway in genitourinary tumors. Future Science OA, 2015, 1, FSO15.	0.9	58
261	Risk of pruritus in cancer patients treated with biological therapies: A systematic review and meta-analysis of clinical trials. Critical Reviews in Oncology/Hematology, 2015, 96, 206-219.	2.0	22
262	Recent Aspects of Sunitinib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma: a Systematic Review of the Literature. Current Urology Reports, 2015, 16, 3.	1.0	12
263	The route to personalized medicine in bladder cancer: where do we stand?. Targeted Oncology, 2015, 10, 325-336.	1.7	14
264	PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises. Cancer Treatment Reviews, 2015, 41, 114-121.	3.4	161
265	Chromium Exposure and Germinal Embryonal Carcinoma: First Two Cases and Review of the Literature. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2015, 78, 1-6.	1.1	17
266	eNOS polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib. Digestive and Liver Disease, 2015, 47, e8.	0.4	0
267	Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?. Journal of Experimental and Clinical Cancer Research, 2015, 34, 10.	3.5	65
268	Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). Journal of Gastrointestinal Cancer, 2015, 46, 109-117.	0.6	15
269	The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. Cell Adhesion and Migration, 2015, 9, 14-21.	1.1	51
270	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. Annals of Surgical Oncology, 2015, 22, 2094-2100.	0.7	72

#	Article	IF	Citations
271	Increased rates of local complication of central venous catheters in the targeted anticancer therapy era: a 2-year retrospective analysis. Supportive Care in Cancer, 2015, 23, 1295-1302.	1.0	14
272	The distinctive molecular, pathological and clinical characteristics ofBRAF-mutant colorectal tumors. Expert Review of Molecular Diagnostics, 2015, 15, 979-987.	1.5	14
273	BAP1,PBRM1andSETD2in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies. Expert Review of Molecular Diagnostics, 2015, 15, 1201-1210.	1.5	78
274	Metabolic alterations in renal cell carcinoma. Cancer Treatment Reviews, 2015, 41, 767-776.	3.4	71
275	KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma. Future Oncology, 2015, 11, 1905-1917.	1.1	11
276	Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target. Cancer Treatment Reviews, 2015, 41, 569-576.	3.4	41
277	Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. European Journal of Cancer, 2015, 51, 942-949.	1.3	47
278	Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients. Supportive Care in Cancer, 2015, 23, 3095-3101.	1.0	44
279	Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Targeted Oncology, 2015, 10, 517-522.	1.7	49
280	Gender differences and outcome of melanoma patients. Journal of Translational Medicine, 2015, 13, P13.	1.8	3
281	High Neutrophil-to-lymphocyte Ratio Persistent During First-line Chemotherapy Predicts Poor Clinical Outcome in Patients with Advanced Urothelial Cancer. Annals of Surgical Oncology, 2015, 22, 1377-1384.	0.7	80
282	Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC Cancer, 2015, 15, 195.	1.1	101
283	Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in patients with clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 113.e1-113.e7.	0.8	15
284	Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer. Expert Opinion on Investigational Drugs, 2015, 24, 809-824.	1.9	43
285	Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?. Future Oncology, 2015, 11, 107-119.	1.1	16
286	Altering macrophage polarization in the tumor environment: the role of response gene to complement 32. Cellular and Molecular Immunology, 2015, 12, 783-784.	4.8	9
287	Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. Expert Opinion on Pharmacotherapy, 2015, 16, 2719-2725.	0.9	66
288	Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer. SpringerPlus, 2015, 4, 255.	1.2	40

#	Article	IF	Citations
289	Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients. Cellular and Molecular Immunology, 2015, 12, 122-124.	4.8	2
290	Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer. Expert Opinion on Investigational Drugs, 2015, 24, 1185-1198.	1.9	4
291	Everolimus and Temsirolimus Are Not the Same Second-Line in Metastatic Renal Cell Carcinoma. A Systematic Review and Meta-Analysis of Literature Data. Clinical Genitourinary Cancer, 2015, 13, 137-141.	0.9	28
292	Panitumumab for the treatment of metastatic colorectal cancer: a review. Immunotherapy, 2015, 7, 721-738.	1.0	6
293	Conditional Survival of Patients Treated With First-Line Chemotherapy for Metastatic Urothelial Cancer. Clinical Genitourinary Cancer, 2015, 13, 244-249.	0.9	10
294	Maintenance therapy for metastatic colorectal cancer. Lancet Oncology, The, 2015, 16, 1281-1282.	5.1	2
295	A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors. Annals of Oncology, 2015, 26, 2341-2346.	0.6	30
296	Addressing the challenges of pancreatic cancer: Future directions for improving outcomes. Pancreatology, 2015, 15, 8-18.	0.5	404
297	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. Journal of Urology, 2015, 193, 41-47.	0.2	58
298	Hyponatraemia is a predictor of clinical outcome for malignant pleural mesothelioma. Supportive Care in Cancer, 2015, 23, 621-626.	1.0	33
299	Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up-to-date review and meta-analysis of clinical trials. International Journal of Cancer, 2015, 136, 1-10.	2.3	47
300	Maspin Staining and Its Use as Biomarker in Lung Cancer. Biomarkers in Disease, 2015, , 345-358.	0.0	3
301	A phase III multicenter trial comparing two different sequences of second/third line therapy		

#	Article	IF	Citations
307	Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2015, 33, 595-595.	0.8	1
308	Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2015, 33, 740-740.	0.8	9
309	The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?. PLoS ONE, 2015, 10, e0120427.	1.1	9
310	Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells.. Oncoscience, 2015, 2, 395-409.	0.9	25
311	Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy. Oncotarget, 2015, 6, 19305-19315.	0.8	18
312	Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management. Oncotarget, 2015, 6, 33982-33992.	0.8	46
313	Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma. Oncotarget, 2015, 6, 32161-32168.	0.8	28
314	Prognostic impact of mismatch repair genes germline defects in colorectal cancer patients: are all mutations equal?. Oncotarget, 2015, 6, 38737-38748.	0.8	25
315	New findings on thymic epithelial tumors: Something is changing. World Journal of Clinical Oncology, 2015, 6, 96.	0.9	5
316	Molecular selection for colorectal cancer (CRC) patients receiving cetuximab: Final results of a prospective study.. Journal of Clinical Oncology, 2015, 33, 596-596.	0.8	0
317	LDH serum levels as prognostic and predictive factor in advanced biliary tract cancer patients treated with first-line chemotherapy.. Journal of Clinical Oncology, 2015, 33, 313-313.	0.8	0
318	Randomized phase III study of panitumumab (pmab) vs. cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia (hypomag) in ASPECCT.. Journal of Clinical Oncology, 2015, 33, 705-705.	0.8	0
319	Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management.. Journal of Clinical Oncology, 2015, 33, 591-591.	0.8	0
320	FOLFIRNOX for advanced pancreatic cancer (aPDAC) according to schedule and dose modifications: Clinical feasibility and impact of supportive care.. Journal of Clinical Oncology, 2015, 33, 372-372.	0.8	0
321	Angiogenic profile and pathological features in the prediction of clinical outcome of advanced renal cell carcinoma patients receiving sunitinib.. Journal of Clinical Oncology, 2015, 33, 458-458.	0.8	0
322	Correlation between everolimus discontinuation or dose reduction induced by stomatitis or cutaneous toxicity and clinical outcome in patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 448-448.	0.8	3
323	Osteopontin (OPN) and interleukin-6 (IL-6) as predictive biomarkers in HCC receiving loco-regional treatment: Preliminary results.. Journal of Clinical Oncology, 2015, 33, e13501-e13501.	0.8	0
324	Multigene profiling in incidentally- and clinically detected prostate cancer.. Journal of Clinical Oncology, 2015, 33, e16107-e16107.	0.8	0

#	Article	IF	Citations
325	Effect of metformin on clinical outcome in advanced HCC patients receiving sorafenib.. Journal of Clinical Oncology, 2015, 33, e15156-e15156.	0.8	0
326	Systemic immune-inflammation index (SII) as prognostic/predictive factor in patients (pts) with metastatic renal cell cancer (mRCC) treated with sunitinib.. Journal of Clinical Oncology, 2015, 33, e15595-e15595.	0.8	0
327	GLIOSTRY (GLIOblastoma regiSTRY) of the AINO (Italian Association of Neuro-Oncology): Analysis of factors influencing survival in glioblastoma patients receiving the nitrosourea fotemustine at first relapse following Stupp regimen.. Journal of Clinical Oncology, 2015, 33, 2054-2054.	0.8	0
328	Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey. PLoS ONE, 2014, 9, e105268.	1.1	33
329	Baseline Neutrophil to Lymphocyte Ratio Correlates with Tumor Stage in Locally Advanced Breast Cancer Patients. Annals of Oncology, 2014, 25, iv113.	0.6	0
330	Neutrophil/Lymphocyte Ratio and Piastrinosis Correlate with Clinical Outcome in Metastatic Colorectal Cancer Patients Receiving Regorafenib. Annals of Oncology, 2014, 25, iv181.	0.6	0
331	Prognosis of Brca1 and Brca2-Related Breast Cancers: are There Differences?. Annals of Oncology, 2014, 25, iv254.	0.6	0
332	Pharmacogenomics of cetuximab in metastatic colorectal carcinoma. Pharmacogenomics, 2014, 15, 1701-1715.	0.6	4
333	Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors. Oncologist, 2014, 19, 966-974.	1.9	84
334	Androgen Receptor Expression in Early Triple-Negative Breast Cancer: Clinical Significance and Prognostic Associations. Cancers, 2014, 6, 1351-1362.	1.7	61
335	Neoadjuvant Therapy in Pancreatic Cancer: An Emerging Strategy. Gastroenterology Research and Practice, 2014, 2014, 1-9.	0.7	31
336	CXC and CC Chemokines as Angiogenic Modulators in Nonhaematological Tumors. BioMed Research International, 2014, 2014, 1-12.	0.9	51
337	Frequency of S492R Mutations in the Epidermal Growth Factor Receptor: Analysis of Plasma Dna from Metastatic Colorectal Cancer Patients Treated with Panitumumab or Cetuximab Monotherapy. Annals of Oncology, 2014, 25, ii109.	0.6	19
338	Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey. Expert Opinion on Pharmacotherapy, 2014, 15, 143-150.	0.9	7
339	Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma. Critical Reviews in Oncology/Hematology, 2014, 92, 208-217.	2.0	29
340	Role of natural and adaptive immunity in renal cell carcinoma response to VEGFRâ€TKIs and mTOR inhibitor. International Journal of Cancer, 2014, 134, 2772-2777.	2.3	57
341	Advanced Digestive Neuroendocrine Tumors. Pancreas, 2014, 43, 212-218.	0.5	46
342	Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. Digestive and Liver Disease, 2014, 46, 182-186.	0.4	40

#	Article	IF	Citations
343	Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. Cancer and Metastasis Reviews, 2014, 33, 321-331.	2.7	27
344	VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICEâ€1 study. International Journal of Cancer, 2014, 135, 1247-1256.	2.3	109
345	The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. BMC Cancer, 2014, 14, 110.	1.1	80
346	Thymic neoplasms: An update on the use of chemotherapy and new targeted therapies. A literature review. Cancer Treatment Reviews, 2014, 40, 495-506.	3.4	15
347	Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncology, The, 2014, 15, 569-579.	5.1	384
348	Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and metaâ€analysis of clinical trials. International Journal of Cancer, 2014, 135, 763-773.	2.3	43
349	Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. Cancer Treatment Reviews, 2014, 40, 271-275.	3.4	84
350	Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 221-231.	3.3	46
351	The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. Expert Opinion on Investigational Drugs, 2014, 23, 925-942.	1.9	32
352	PR20 Biology of BRCA-related triple-negative breast cancer: which is the difference with the others?. Breast, 2014, 23, S8.	0.9	0
353	Neuroendocrine differentiation in prostate cancer: Novel morphological insights and future therapeutic perspectives. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 630-637.	3.3	38
354	The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology (ESMO). Annals of Oncology, 2014, 25, 9-15.	0.6	52
355	The â€œangiogenetic ladderâ€, step-wise angiogenesis inhibition in metastatic colorectal cancer. Cancer Treatment Reviews, 2014, 40, 934-941.	3.4	16
356	P80 ANGIOGENESIS POLYMORPHISMS PROFILE IN THE PREDICTION OF CLINICAL OUTCOME OF ADVANCED HCC PATIENTS RECEIVING SORAFENIB: COMBINED ANALYSIS OF VEGF AND HIF-1Î±. THE ALICE-2 STUDY. Journal of Hepatology, 2014, 60, S93.	1.8	0
357	The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment. Molecules, 2014, 19, 6393-6406.	1.7	56
358	LDH serum levels as a predictive factor for global outcome in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management.. Journal of Clinical Oncology, 2014, 32, 497-497.	0.8	2
359	Beyond RAS: The Role of Epidermal Growth Factor Receptor (EGFR) and its Network in the Prediction of Clinical Outcome During Anti-EGFR Treatment in Colorectal Cancer Patients. Current Drug Targets, 2014, 15, 1225-1230.	1.0	7
360	Locally advanced rectal cancer: The importance of a multidisciplinary approach. World Journal of Gastroenterology, 2014, 20, 17279.	1.4	24

#	Article	IF	Citations
361	Correlation of KRAS mutational state with the expression of the hedgehog pathway in patients with pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, 227-227.	0.8	0
362	Angiogenesis genotyping, LDH serum levels, and treatment efficacy for advanced hepatocellular carcinoma patients receiving sorafenib.. Journal of Clinical Oncology, 2014, 32, 245-245.	0.8	0
363	Cancer stem cells profile and clinical outcome in stage III colon cancer patients receiving adjuvant oxaliplatin-based chemotherapy.. Journal of Clinical Oncology, 2014, 32, 474-474.	0.8	0
364	Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients.. Journal of Clinical Oncology, 2014, 32, 64-64.	0.8	0
365	Correlation of distinctive angiogenetic profiles with clinical outcome for different treatment sequences in mRCC.. Journal of Clinical Oncology, 2014, 32, 474-474.	0.8	0
366	Differences in terms of progression-free survival (PFS) and overall survival (OS) in patients treated with first-line sorafenib, sunitinib, and pazopanib for late relapsing (>5 years) renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 421-421.	0.8	0
367	High neutrophil to lymphocyte ratio persistent during first-line chemotherapy to predict clinical outcome in patients with advanced urothelial cancer.. Journal of Clinical Oncology, 2014, 32, 4540-4540.	0.8	0
368	Pretreatment neutrophil to lymphocyte ratio may be an useful tool in predicting survival in early triple-negative breast cancer patients.. Journal of Clinical Oncology, 2014, 32, 1111-1111.	0.8	0
369	Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, 4025-4025.	0.8	3
370	KRAS: To be or not to be targeted? Biologic and computational analyses in pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, e15207-e15207.	0.8	1
371	Single-nucleotide polymorphisms (SNPs) associated with outcome: The first experience in thymic tumors.. Journal of Clinical Oncology, 2014, 32, e18557-e18557.	0.8	0
372	VEGF and VEGFRs polymorphisms analysis in advanced renal cell carcinoma tissues: Is heterogeneity ever the answer?. Journal of Clinical Oncology, 2014, 32, 4533-4533.	0.8	0
373	Prognostic factors in patients with pancreatic metastases from renal cell carcinoma (PM-RCC): Room for thinking about the role of surgery?. Journal of Clinical Oncology, 2014, 32, e15563-e15563.	0.8	0
374	Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1.. Journal of Clinical Oncology, 2014, 32, e15140-e15140.	0.8	0
375	Abstract 2220: Impact of single-nucleotide polymorphisms (SNPs) on thymic hyperplasia and tumors outcome. , 2014, , .		0
376	Gastric cancer: toward a cisplatin-free disease?. Journal of Gastrointestinal Oncology, 2014, 5, 318-22.	0.6	2
377	Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. Journal of Biological Regulators and Homeostatic Agents, 2014, 28, 555-63.	0.7	33
378	Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma. Journal of Neuro-Oncology, 2013, 113, 397-401.	1.4	17

#	Article	IF	Citations
379	Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. Cancer, 2013, 119, 3429-3435.	2.0	26
380	State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: A literature review. Critical Reviews in Oncology/Hematology, 2013, 88, 75-86.	2.0	61
381	Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells. British Journal of Cancer, 2013, 109, 1040-1050.	2.9	65
382	Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients. Pharmacogenomics, 2013, 14, 1991-1998.	0.6	17
383	Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. British Journal of Cancer, 2013, 109, 1755-1759.	2.9	79
384	Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. European Journal of Cancer, 2013, 49, 3616-3624.	1.3	78
385	Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy, 2013, 62, 1757-1768.	2.0	110
386	Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials. Prostate Cancer and Prostatic Diseases, 2013, 16, 323-327.	2.0	10
387	Adjuvant chemotherapy in colon cancer: Can we improve quality of care?. Digestive and Liver Disease, 2013, 45, 637-638.	0.4	0
388	Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. Critical Reviews in Oncology/Hematology, 2013, 88, 272-283.	2.0	27
389	Cetuximab: still an option in the treatment of pancreatic cancer?. Expert Opinion on Biological Therapy, 2013, 13, 791-801.	1.4	17
390	Resected biliary tract cancers: A novel clinicalâ€“pathological score correlates with global outcome. Digestive and Liver Disease, 2013, 45, 70-74.	0.4	10
391	The Tower of Babel of liver metastases from colorectal cancer: Are we ready for one language?. Critical Reviews in Oncology/Hematology, 2013, 85, 332-341.	2.0	8
392	Role of Î²4 integrin in HER-3-negative, K-RAS wild-type metastatic colorectal tumors receiving cetuximab. Future Oncology, 2013, 9, 1207-1214.	1.1	5
393	Transient Sunitinib Resistance in Gastrointestinal Stromal Tumors. New England Journal of Medicine, 2013, 368, 2042-2043.	13.9	31
394	VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib. British Journal of Cancer, 2013, 108, 1126-1132.	2.9	71
395	Progress of Molecular Targeted Therapies for Advanced Renal Cell Carcinoma. BioMed Research International, 2013, 2013, 1-9.	0.9	35
396	Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Annals of Oncology, 2013, 24, 2875-2880.	0.6	48

#	Article	IF	Citations
397	HER2I Resistance. Annals of Oncology, 2013, 24, ix17.	0.6	0
398	A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel. Journal of Cardiovascular Pharmacology, 2013, 61, 495-504.	0.8	4
399	Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. OncoTargets and Therapy, 2013, 6, 563.	1.0	22
400	Clinical Evidence for Three Distinct Gastric Cancer Subtypes: Time for a New Approach. PLoS ONE, 2013, 8, e78544.	1.1	14
401	Different effects of sunitinib, sorafenib, and pazopanib on inducing cancer cell death: The role of autophagy.. Journal of Clinical Oncology, 2013, 31, 270-270.	0.8	2
402	Cancer Stem Cell Gene Profile as Predictor of Relapse in High Risk Stage II and Stage III, Radically Resected Colon Cancer Patients. PLoS ONE, 2013, 8, e72843.	1.1	36
403	Essential Role of Gli Proteins in Glioblastoma Multiforme. Current Protein and Peptide Science, 2013, 14, 133-140.	0.7	53
404	Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?. Current Cancer Drug Targets, 2013, 13, 313-325.	0.8	8
405	Effect of VEGF and VEGFR polymorphisms on clinical outcome and response in patients with advanced renal cell carcinoma receiving first-line treatment.. Journal of Clinical Oncology, 2013, 31, 388-388.	0.8	1
406	Targeting Hedgehog in pancreatic cancer: An innovative approach but not for all tumors.. Journal of Clinical Oncology, 2013, 31, 205-205.	0.8	0
407	Tumor cancer stem cell genetic profile as predictor of relapse in stage II and III radically resected colon cancer patients.. Journal of Clinical Oncology, 2013, 31, 429-429.	0.8	0
408	Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2013, 31, 431-431.	0.8	1
409	Locally advanced or metastatic pancreatic tumors: Molecular biology may help to know it and to select the optimal treatment.. Journal of Clinical Oncology, 2013, 31, 201-201.	0.8	0
410	The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFR) polymorphisms in the prediction of clinical outcome for advanced hepatocellular carcinoma receiving sorafenib.. Journal of Clinical Oncology, 2013, 31, 208-208.	0.8	0
411	Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practice. Anticancer Research, 2013, 33, 2737-42.	0.5	24
412	VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma. Anticancer Research, 2013, 33, 5017-22.	0.5	12
413	The MaiSON Project (Italy). Developing integration strategies for oncology organizations/associations through a participatory approach. Tumori, 2013, 99, 122-4.	0.6	0
414	Compliance with breast and cervical cancer screening programs in women: results from a population-based study. Tumori, 2013, 99, 565-71.	0.6	5

#	Article	IF	Citations
415	Locally advanced versus metastatic pancreatic cancer: two different diseases with two different treatment approaches?. Chinese Clinical Oncology, 2013, 2, 26.	0.4	0
416	Present and Future of Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: Analysis of Hematologic Toxicity. Recent Patents on Anti-infective Drug Discovery, 2012, 7, 104-110.	0.5	20
417	Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Annals of Oncology, 2012, 23, 2072-2077.	0.6	108
418	Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. British Journal of Cancer, 2012, 106, 799-804.	2.9	97
419	A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. Annals of Oncology, 2012, 23, 1081-1082.	0.6	4
420	Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder. Advances in Urology, 2012, 2012, 1-5.	0.6	22
421	Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecanâ€“cetuximab. Annals of Oncology, 2012, 23, 1706-1712.	0.6	34
422	1035 THE ROLE OF VEGF AND VEGFR POLYMORPHISMS IN THE PREDICTION OF CLINICAL OUTCOME FOR ADVANCED HEPATOCELLULAR CARCINOMA RECEIVING SORAFENIB. Journal of Hepatology, 2012, 56, S405.	1.8	0
423	Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?. Annals of Oncology, 2012, 23, 2313-2318.	0.6	170
424	Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer â€“ Differential treatment strategies for subtypes of early gastroesophageal cancer. European Journal of Cancer, 2012, 48, 2941-2953.	1.3	129
425	Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. Journal of Translational Medicine, 2012, 10, 71.	1.8	25
426	Sub-cellular localization analysis of MSH6 missense mutations does not reveal an overt MSH6 nuclear transport impairment. Familial Cancer, 2012, 11, 675-680.	0.9	2
427	Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. Digestive and Liver Disease, 2012, 44, 74-79.	0.4	3
428	Nuclear factor-ÎºB predicts outcome in locally advanced rectal cancer patients receiving neoadjuvant radio-chemotherapy. Digestive and Liver Disease, 2012, 44, 617-622.	0.4	10
429	Role of Vascular Endothelial Growth Factor (VEGF) and VEGF-R Genotyping in Guiding the Metastatic Process in pT4a Resected Gastric Cancer Patients. PLoS ONE, 2012, 7, e38192.	1.1	15
430	Beta 4 Integrin Polymorphism Mediate an Alternative Resistance Pathway in HER-3 Negative, K-RAS Wild Type Metastatic Colorectal Patients Receiving Irinotecan Cetuximab. Annals of Oncology, 2012, 23, ix86.	0.6	0
431	Potential Clinical Application and Trials. Annals of Oncology, 2012, 23, ix37.	0.6	0
432	Clinical Outcome of advanced Gastric Cancer (GC) Patients Receiving First-Line Chemotherapy According to Tumour Histology and Location. Annals of Oncology, 2012, 23, ix250.	0.6	0

#	Article	IF	Citations
433	The Role of Hedgehog (HH) Signaling in the Prediction of Clinical Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC). Annals of Oncology, 2012, 23, ix533.	0.6	0
434	Cancer Stem Cell Genetic Profile as Predictor of Relapse in Radically Resected Colorectal Cancer. Annals of Oncology, 2012, 23, ix86-ix87.	0.6	0
435	Primary Resistance to First-Line Bevacizumab in Metastatic Colorectal Cancer: Implications on Prognosis. Annals of Oncology, 2012, 23, ix219-ix220.	0.6	0
436	The Role of Tumour Vascular Endothelial Growth Factor (VEGF) and Vascular Endothelial Growth Factor Receptors (VEGFR) Polymorphisms in the Prediction of Clinical Outcome for advanced Hepatocellular Carcinoma Receiving Sorafenib. Annals of Oncology, 2012, 23, ix243.	0.6	0
437	Prognostic Factors in Early Stage Non-Small Cell Lung Cancer (NSCLC): The Importance of Number of Resected Lymph Nodes and Vascular Invasion. Annals of Oncology, 2012, 23, ix387.	0.6	0
438	Phase II Trial of Panitumumab in Combination with Oxaliplatin and Capecitabine Chemotherapy as 1st Line Therapy in Patients with Colorectal Cancer and Advanced Liver Metastases: The Metapan Study. Annals of Oncology, 2012, 23, ix205-ix206.	0.6	1
439	Pancreatic Ductal Adenocarcinoma: A Homogeneous Morphologically but Molecularly Heterogeneous Tumor. IMPLICATIONS for its Management. Annals of Oncology, 2012, 23, ix239.	0.6	0
440	Prognostic Significance of EGFR, HER-2, CEA on Circulatingtumour Cells (CTCS) in Patients with Metastatic Non-Small-Cell Lung Cancer (MNSCLC). Annals of Oncology, 2012, 23, ix431.	0.6	0
441	Clinical Impact of [11C]-Methionine Positron Emission Tomography on the Treatment of Primary and Recurrent Gliomas. Annals of Oncology, 2012, 23, ix148.	0.6	1
442	Temperament and Character Traits Associated with Health-Related Quality of Life in Cancer Patients. Tumori, 2012, 98, 377-384.	0.6	7
443	Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study. Oncology Letters, 2012, 4, 799-801.	0.8	10
444	FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemotherapy and Pharmacology, 2012, 69, 1641-1645.	1.1	78
445	Performance at Preoperative Stair-Climbing Test Is Associated With Prognosis After Pulmonary Resection in Stage I Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2012, 93, 1796-1800.	0.7	46
446	A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis, 2012, 15, 141-150.	3.7	48
447	Selecting the Best Treatment for an Individual Patient. Recent Results in Cancer Research, 2012, 196, 307-318.	1.8	8
448	The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management. PLoS ONE, 2012, 7, e32653.	1.1	47
449	Temperament and character traits associated with health-related quality of life in cancer patients. Tumori, 2012, 98, 377-84.	0.6	4
450	Palliative Treatment. , 2012, , 209-214.		0

#	Article	IF	Citations
451	Adjuvant Treatment After Surgical Resection. , 2012, , 187-194.		0
452	The role of tumor vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) polymorphisms in the prediction of clinical outcome for patients with advanced renal cell carcinoma receiving first-line sunitinib.. Journal of Clinical Oncology, 2012, 30, 380-380.	0.8	0
453	Correlation of activated AKT and MAPK expression in liver metastases with clinical outcome in colorectal cancer patients receiving irinotecan/cetuximab treatment.. Journal of Clinical Oncology, 2012, 30, 449-449.	0.8	0
454	Intensive up-front treatment versus a sequential approach in advanced gastric cancer patients: Does first-line matter?. Journal of Clinical Oncology, 2012, 30, e14663-e14663.	0.8	0
455	Tumour Vascular Endothelial Growth Factor (VEGF) and Vascular Endothelial Growth Factor Receptors (VEGFR) Polymorphisms and Clinical Outcome in Advanced Renal Cell Carcinoma Patients Receiving First Line Sunitinib. Annals of Oncology, 2012, 23, ix274.	0.6	0
456	Angiogenetic pathway as a therapeutic target in renal cell carcinoma. , 2012, 34, 15-22.		1
457	Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. Journal of Clinical Oncology, 2011, 29, 2011-2019.	0.8	1,713
458	8743 POSTER Efficacy of Fotemustine in Recurrent Malignant Glioma According to Time to Adjuvant Temozolomide Failure â€“ a Pooled Analysis. European Journal of Cancer, 2011, 47, S586.	1.3	0
459	6612 POSTER The Role of Vascular Endothelial Growth Factor (VEGF) and VEGF-receptors Genotyping in Guiding the Metastatic Process in Radically Resected Gastric Cancer Patients. European Journal of Cancer, 2011, 47, S475.	1.3	0
460	The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis. Digestive and Liver Disease, 2011, 43, 194-198.	0.4	7
461	5-fluorouracil pharmacogenomics: still rocking after all these years?. Pharmacogenomics, 2011, 12, 251-265.	0.6	54
462	Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options. Cancer Treatment Reviews, 2011, 37, 169-177.	3.4	49
463	1005 ORAL HER-3, IGF-1, NF K-B and EGFR Gene Copy Number in the Prediction of Clinical Outcome for Colorectal Cancer Patients Receiving Irinotecan-cetuximab. European Journal of Cancer, 2011, 47, S98.	1.3	0
464	PP 22 Analysis of HER-3, insulin-growth factor-1 (IGF-1), nuclear factor k-B (NF-kB) and epidermal growth factor receptor (EGFR) gene copy number (GCN) in the prediction of clinical outcome for K-RAS wild type colorectal cancer patients receiving irinotecanâ€“cetuximab. European Journal of Cancer, 2011, 47, S29.	1.3	1
465	PP 23 The role of vascular endothelial growth factor (VEGF) and VEGF-receptors genotyping in guiding the metastatic process in radically resected gastric cancer patients. European Journal of Cancer, 2011, 47, S30.	1.3	0
466	Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. British Journal of Cancer, 2011, 104, 1786-1790.	2.9	65
467	Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. Cancer Chemotherapy and Pharmacology, 2011, 68, 37-43.	1.1	15
468	The Role of HERâ€3 Expression in the Prediction of Clinical Outcome for Advanced Colorectal Cancer Patients Receiving Irinotecan and Cetuximab. Oncologist, 2011, 16, 53-60.	1.9	55

#	Article	IF	Citations
469	Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients. Annals of Oncology, 2011, 22, 897-902.	0.6	9
470	Professional failure: how do oncologists feel it?. Annals of Oncology, 2011, 22, 2696-2697.	0.6	1
471	Combination of the immunocytokine F16-IL2 with doxorubicin or paclitaxel in patients with solid tumors: Results from two phase Ib trials.. Journal of Clinical Oncology, 2011, 29, 2595-2595.	0.8	8
472	The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan/cetuximab.. Journal of Clinical Oncology, 2011, 29, 404-404.	0.8	2
473	A novel approach to manage skin toxicity caused by cetuximab and panitumumab.. Journal of Clinical Oncology, 2011, 29, 616-616.	0.8	0
474	Efficacy of nitrosourea-based chemotherapy in recurrent malignant glioma according to time to adjuvant temozolomide failure: A pooled analysis.. Journal of Clinical Oncology, 2011, 29, 2060-2060.	0.8	11
475	Relationship of number of resected lymph nodes in early-stage non-small cell lung cancer (NSCLC) and survival.. Journal of Clinical Oncology, 2011, 29, e17509-e17509.	0.8	1
476	Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice. Tumori, 2011, 97, 275-9.	0.6	1
477	Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensity. Tumori, 2011, 97, 449-53.	0.6	0
478	Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2010, 66, 559-566.	1.1	5
479	Novel Perspectives for the Treatment of Gastric Cancer: From a Global Approach to a Personalized Strategy. Current Oncology Reports, 2010, 12, 175-185.	1.8	13
480	Insulinâ€like growth factor 1 expression correlates with clinical outcome in Kâ€RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. International Journal of Cancer, 2010, 127, 1941-1947.	2.3	67
481	Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer. Core Evidence, 2010, 5, 61.	4.7	11
482	Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. Annals of Oncology, 2010, 21, 655-661.	0.6	84
483	Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, v55-v58.	0.6	134
484	Chemotherapy-Free Intervals in Patients With Metastatic Colorectal Cancer: A Tale of Two Cities?. Journal of Clinical Oncology, 2010, 28, e268-e269.	0.8	1
485	Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?. Lung Cancer, 2010, 68, 433-437.	0.9	17
486	Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. Journal of Experimental and Clinical Cancer Research, 2010, 29, 164.	3.5	39

#	Article	IF	Citations
487	Sorafenib plus chemotherapy versus chemotherapy alone in advanced pancreatic cancer: A randomized phase II trial.. Journal of Clinical Oncology, 2010, 28, 4066-4066.	0.8	6
488	Combinations of the immunocytokine F16-IL2 with doxorubicin or with paclitaxel investigated in phase Ib studies in patients with advanced solid tumors.. Journal of Clinical Oncology, 2010, 28, e13017-e13017.	0.8	9
489	Correlation of tumor integrins and peritoneal carcinosis capability of gastric cancer.. Journal of Clinical Oncology, 2010, 28, e14539-e14539.	0.8	0
490	Abstract P5-12-05:9Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. , 2010, , .		0
491	Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. Annals of Oncology, 2009, 20, 1062-1067.	0.6	18
492	Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2. Expert Opinion on Pharmacotherapy, 2009, 10, 2467-2478.	0.9	6
493	Pancreatic cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2009, 20, iv37-iv40.	0.6	27
494	Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Annals of Oncology, 2009, 20, 227-230.	0.6	294
495	Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer, 2009, 9, 303.	1.1	66
496	Association of progressionâ€free survival, overall survival, and patientâ€reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer, 2009, 115, 1544-1554.	2.0	127
497	Women and lung cancer: Clinical and molecular profiling as a determinate for treatment decisions. Critical Reviews in Oncology/Hematology, 2009, 69, 223-236.	2.0	11
498	Locally Advanced Rectal Cancer Patients Receiving Radio-Chemotherapy: A Novel Clinicalâ€“Pathologic Score Correlates With Global Outcome. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1437-1443.	0.4	4
499	Social Support Networks and Depression of Women Suffering from Early-Stage Breast Cancer: A Case Control Study. Journal of Psychosocial Oncology, 2009, 27, 216-229.	0.6	10
500	Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). British Journal of Cancer, 2009, 101, 1261-1268.	2.9	130
501	Toward molecularly selected chemotherapy for advanced gastric cancer: State of the art and future perspectives. Cancer Treatment Reviews, 2009, 35, 451-462.	3.4	24
502	Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1. Expert Opinion on Pharmacotherapy, 2009, 10, 2245-2258.	0.9	12
503	Hepatocellular carcinoma: The beginning of a long journey. Digestive and Liver Disease, 2009, 41, 707-708.	0.4	0
504	An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy. Lung Cancer, 2009, 64, 199-206.	0.9	20

#	Article	IF	Citations
505	PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 2622-2629.	0.8	402
506	Cetuximab plus FOLFIRI first line in patients (pts) with metastatic colorectal cancer (mCRC): A quality-of-life (QoL) analysis of the CRYSTAL trial. Journal of Clinical Oncology, 2009, 27, 4076-4076.	0.8	15
507	Correlation of insulin-like growth factor 1 (IGF-1) expression and clinical outcome in K-RAS wild-type colorectal cancer patients treated with cetuximab-irinotecan. Journal of Clinical Oncology, 2009, 27, 4017-4017.	0.8	5
508	Epidermal growth factor receptor gene promoter methylation in primary colorectal tumors and corresponding metastatic sites: a new perspective for an "old" therapeutic target. , 2009, 31, 417-23.		2
509	A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2008, 62, 673-678.	1.1	18
510	Pancreatic cancer: Progress in cancer therapy. Critical Reviews in Oncology/Hematology, 2008, 67, 27-38.	2.0	32
511	A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-ĸB activation. British Journal of Cancer, 2008, 98, 71-76.	2.9	41
512	Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. British Journal of Cancer, 2008, 98, 143-147.	2.9	78
513	Multicentric, Randomized Phase III Trial of Two Different Adjuvant Chemotherapy Regimens plus Three Versus Twelve Months of Trastuzumab in Patients with HER2-Positive Breast Cancer (Short-HER Trial;) Tj ETQq1 1 0.784314 rgBT /Ove	1.8	82
514	Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group. European Journal of Cancer, 2008, 44, 182-194.	1.3	93
515	Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncology, The, 2008, 9, 39-44.	5.1	130
516	Oral treatment for gastric cancer: new choices, better choices?. Lancet Oncology, The, 2008, 9, 188-189.	5.1	5
517	KIT and PDGFRÎ± mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based study. Annals of Oncology, 2008, 19, 706-710.	0.6	29
518	Adjuvant Chemotherapy in Completely Resected Gastric Cancer: A Randomized Phase III Trial Conducted by GOIRC. Journal of the National Cancer Institute, 2008, 100, 388-398.	3.0	123
519	Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Annals of Oncology, 2008, 19, 1293-1298.	0.6	74
520	Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: A randomised phase II trial. Journal of Clinical Oncology, 2008, 26, 13521-13521.	0.8	1
521	Ca 19.9 as an early predictor of response to first- and second-line treatment in patients with pancreatic cancer. Journal of Clinical Oncology, 2008, 26, 15547-15547.	0.8	2
522	Multicenter phase II study of temozolomide therapy for brain metastases in patients with malignant melanoma, breast cancer, or non-small cell lung cancer: Final results. Journal of Clinical Oncology, 2008, 26, 2032-2032.	0.8	1

#	Article	IF	Citations
523	Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment. Journal of Clinical Oncology, 2008, 26, 4003-4003.	0.8	21
524	Cetuximab in combination with cisplatin and docetaxel as first-line treatment in patients with locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (Italian phase II) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	gB	12
525	Efficacy and toxicity of a low dose regimen of capecitabine and oral vinorelbine. Journal of Clinical Oncology, 2008, 26, 12013-12013.	0.8	0
526	Nuclear factor-kB (NF-kB) predicts outcome in locally advanced rectal cancer patients receiving radio-chemotherapy. Journal of Clinical Oncology, 2008, 26, 22122-22122.	0.8	0
527	Response: Re: Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients with 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. Journal of the National Cancer Institute, 2007, 99, 1346-1347.	3.0	1
528	Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Annals of Oncology, 2007, 18, 1660-1665.	0.6	116
529	Nuclear Factor-kB Tumor Expression Predicts Response and Survival in Irinotecan-Refractory Metastatic Colorectal Cancer Treated With Cetuximab-Irinotecan Therapy. Journal of Clinical Oncology, 2007, 25, 3930-3935.	0.8	121
530	Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. Journal of the National Cancer Institute, 2007, 99, 601-607.	3.0	96
531	Molecular Biology for Stage II Colorectal Cancer: The Jury Is Still Out. Journal of Clinical Oncology, 2007, 25, 2861-2861.	0.8	5
532	Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Annals of Oncology, 2007, 18, 510-517.	0.6	258
533	Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab. Journal of Clinical Oncology, 2007, 25, 3238-3245.	0.8	321
534	COX-2 and NF-KB Overexpression Is Common in Pancreatic Cancer but Does Not Predict for COX-2 Inhibitors Activity in Combination With Gemcitabine and Oxaliplatin. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 526-530.	0.6	34
535	â€œBiliary tract cancers: Molecular profiling as a tool for treatment decisions. A literature reviewâ€• [Cancer Treatment Reviews 32(5) (2006) 333â€“347]. Cancer Treatment Reviews, 2007, 33, 497.	3.4	0
536	[354] THE SELECTIVE INHIBITION OF THE NA+/H+ EXCHANGER BY CARIPORIDE INCREASES THE ANTINEOPLASTIC EFFECT OF GEMCITABINE IN HUMAN CHOLANGIOCARCINOMA CELLS THROUGH MODULATION OF PHARMACORESISTANCE. Journal of Hepatology, 2007, 46, S138.	1.8	0
537	Chemotherapy for advanced gastric cancer: across the years for a standard of care. Expert Opinion on Pharmacotherapy, 2007, 8, 797-808.	0.9	41
538	Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options. British Journal of Cancer, 2007, 97, 92-97.	2.9	39
539	Mucinous Rectal Adenocarcinoma Can Be Associated to Tumor Downstaging after Preoperative Chemoradiotherapy. Diseases of the Colon and Rectum, 2007, 50, 1594-1603.	0.7	57
540	Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. Journal of Clinical Oncology, 2007, 25, 4000-4000.	0.8	193

#	Article	IF	Citations
541	Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. Lung Cancer, 2006, 53, 103-109.	0.9	33
542	Biliary tract cancers: Molecular profiling as a tool for treatment decisions. A literature review. Cancer Treatment Reviews, 2006, 32, 333-347.	3.4	5
543	Capecitabine and Mitomycin c May be an Effective Treatment Option for Third-line Chemotherapy in Advanced Colorectal Cancer. Tumori, 2006, 92, 384-388.	0.6	17
544	Paclitaxel and Epirubicin Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil for Patients With Stage IIIC Breast Cancer With Ten or More Involved Axillary Lymph Nodes. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 380-384.	0.6	2
545	Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. British Journal of Cancer, 2006, 95, 445-449.	2.9	40
546	Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases. International Journal of Radiation Oncology Biology Physics, 2006, 65, 25-32.	0.4	24
547	Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial. BMC Cancer, 2006, 6, 125.	1.1	32
548	Anemia may influence the outcome of patients undergoing neo-adjuvant treatment of rectal cancer. Annals of Oncology, 2006, 17, 1661-1664.	0.6	25
549	New target therapies in advanced pancreatic cancer. Annals of Oncology, 2006, 17, v148-v152.	0.6	24
550	Diagnosis, Management and Clinical Outcome of Bone Metastases in Breast Cancer Patients: Results from a Prospective, Multicenter Study. Oncology, 2006, 71, 374-381.	0.9	14
551	Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice. Expert Opinion on Therapeutic Targets, 2006, 10, 281-287.	1.5	4
552	Pharmacogenetic Profiling and Clinical Outcome of Patients With Advanced Gastric Cancer Treated With Palliative Chemotherapy. Journal of Clinical Oncology, 2006, 24, 1883-1891.	0.8	129
553	Phase II study of cetuximab plus FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study): Preliminary results. Journal of Clinical Oncology, 2006, 24, 4031-4031.	0.8	6
554	Over-D1 dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients. British Journal of Cancer, 2005, 92, 1051-1054.	2.9	15
555	Molecular Profile and Clinical Variables in Brca1-Positive Breast Cancers. A Population-Based Study. Tumori, 2005, 91, 505-512.	0.6	13
556	Adjuvant Systemic Therapies in Patients with Colorectal Cancer: An Audit on Clinical Practice in Italy. Tumori, 2005, 91, 472-476.	0.6	6
557	Hepatic Artery Administration of Docetaxel in Liver Metastases from Breast Carcinoma: A Feasibility Study. Tumori, 2005, 91, 121-125.	0.6	2
558	Prognostic Role of Thymidylate Synthase Polymorphisms in Gastric Cancer Patients Treated with Surgery and Adjuvant Chemotherapy. Clinical Cancer Research, 2005, 11, 3778-3783.	3.2	65

#	Article	IF	Citations
559	Interleukin 1B gene (IL-1B) and interleukin 1 receptor antagonist gene (IL-1RN) polymorphisms in Helicobacter pylori-negative gastric cancer of intestinal and diffuse histotype. Annals of Oncology, 2005, 16, 887-892.	0.6	62
560	Pre-operative treatment modalities in gastric cancer patients. Annals of Oncology, 2005, 16, iv106-iv109.	0.6	0
561	The Role of 5-Fluorouracil (5-FU) Reintroduction with Irinotecan or Oxaliplatin in Truly 5-FU-Refractory Advanced Colorectal Cancer Patients. Oncology, 2005, 68, 212-216.	0.9	4
562	Prognostic Role of Interleukin-1Î² Gene and Interleukin-1 Receptor Antagonist Gene Polymorphisms in Patients With Advanced Gastric Cancer. Journal of Clinical Oncology, 2005, 23, 2339-2345.	0.8	56
563	Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancers. Lung Cancer, 2005, 49, 371-376.	0.9	36
564	High-risk radically resected gastric cancer patients do not benefit of an adjuvant cisplatin containing regimen. Journal of Clinical Oncology, 2005, 23, 4023-4023.	0.8	1
565	Prognostic role of thymidylate synthase (TS) gene polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Journal of Clinical Oncology, 2005, 23, 4044-4044.	0.8	1
566	The presence of bone (BM) and concomitant non-bone metastases (cNBM) significantly worsens the 2-year overall survival (OS) in breast cancer (BC) patients (PTS): Update of results in the moon study. Journal of Clinical Oncology, 2005, 23, 774-774.	0.8	13
567	A novel clinical-pathological score correlates with global outcome of locally advanced rectal cancer patients receiving neoadjuvant chemo-radiotherapy. Journal of Clinical Oncology, 2005, 23, 3667-3667.	0.8	0
568	Early Detection of Recurrences in the Follow-up of Primary Breast Cancer in an Asymptomatic or Symptomatic Phase. Tumori, 2004, 90, 276-279.	0.6	13
569	Prognostic Analysis of E-Cadherin Gene Promoter Hypermethylation in Patients with Surgically Resected, Node-Positive, Diffuse Gastric Cancer. Clinical Cancer Research, 2004, 10, 2784-2789.	3.2	83
570	Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs. Annals of Oncology, 2004, 15, 489-492.	0.6	47
571	Predictive and Prognostic Role of E-Cadherin Protein Expression in Patients with Advanced Gastric Carcinomas Treated with Palliative Chemotherapy. Tumor Biology, 2004, 25, 106-110.	0.8	15
572	Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted Monoclonal Antibodies. Journal of Clinical Oncology, 2004, 22, 4772-4778.	0.8	235
573	High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). British Journal of Cancer, 2004, 90, 1521-1525.	2.9	58
574	Cancer of pancreas. Critical Reviews in Oncology/Hematology, 2004, 50, 147-155.	2.0	19
575	Association of thymidylate synthase polymorphisms with gastric cancer susceptibility. International Journal of Cancer, 2004, 112, 1010-1014.	2.3	46
576	A costâ€“benefit analysis of chemotherapy for gastric cancer. Expert Opinion on Pharmacotherapy, 2004, 5, 2109-2114.	0.9	2

#	Article	IF	Citations
577	Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treatment Reviews, 2004, 30, 451-459.	3.4	65
578	Over D1 lymph-nodes dissection may question the value of post-operative radiotherapy as a part of an adjuvant program in radically resected gastric cancer patients. Journal of Clinical Oncology, 2004, 22, 4041-4041.	0.8	2
579	Weekly oxaliplatin, fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer (AGC). Journal of Clinical Oncology, 2004, 22, 4237-4237.	0.8	2
580	Chemotherapy use at the end of life: An analysis of the decision making process. Journal of Clinical Oncology, 2004, 22, 6081-6081.	0.8	2
581	Predictive and prognostic role of E-cadherin expression in patients with advanced gastric cancer treated with palliative chemotherapy. Journal of Clinical Oncology, 2004, 22, 9632-9632.	0.8	0
582	Weekly oxaliplatin, fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer (AGC). Journal of Clinical Oncology, 2004, 22, 4237-4237.	0.8	1
583	Adjuvant therapies in patients with colorectal cancer: An audit on clinical practice in Italy. Journal of Clinical Oncology, 2004, 22, 3648-3648.	0.8	0
584	Predictive and prognostic role of E-cadherin expression in patients with advanced gastric cancer treated with palliative chemotherapy. Journal of Clinical Oncology, 2004, 22, 9632-9632.	0.8	0
585	Perioperative anemia as prognostic factor in patients undergoing resection for non-small cell lung cancer. Journal of Clinical Oncology, 2004, 22, 7179-7179.	0.8	0
586	The Combination of Gemcitabine and Vinorelbine is an Active Regimen as Second-Line Therapy in Patients with Metastatic Breast Cancer Pretreated with Taxanes and/or Anthracyclines: a Phase Iâ€“II Study. Breast Cancer Research and Treatment, 2003, 78, 29-36.	1.1	22
587	Pain and its treatment in hospitalized patients with metastatic cancer. Supportive Care in Cancer, 2003, 11, 587-592.	1.0	36
588	HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer, 2003, 99, 310-315.	2.0	42
589	Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas. Diagnostic Cytopathology, 2003, 28, 142-146.	0.5	42
590	Carcinoma of pancreatic body and tail: are there improvements in diagnosis and treatment modalities over the past decade?. Digestive and Liver Disease, 2003, 35, 421-427.	0.4	12
591	Effective prevention of 5-fluorouracilâ€“induced superficial phlebitis by ketoprofen lysine salt gel. American Journal of Medicine, 2003, 115, 415-417.	0.6	5
592	Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients. Lung Cancer, 2003, 41, 101-106.	0.9	32
593	Patterns of recurrence of bronchioloalveolar cell carcinoma after surgical resection: a radiological, histological, and immunohistochemical study. Lung Cancer, 2003, 42, 319-326.	0.9	47
594	The Role of Levamisole in the Adjuvant Treatment of Stage III Colon Cancer Patients: A Randomized Trial of 5-Fluorouracil and Levamisole Versus 5-Fluorouracil Alone. Cancer Investigation, 2003, 21, 701-707.	0.6	16

#	Article	IF	Citations
595	Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukesâ€™ B colorectal cancer patients: how much evidence is enough?. Annals of Oncology, 2003, 14, 1026-1038.	0.6	114
596	Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors. Annals of Oncology, 2003, 14, ii25-ii29.	0.6	32
597	A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer. British Journal of Cancer, 2003, 89, 1428-1432.	2.9	22
598	Treatment of Metastatic Colorectal Cancer With Monoclonal Antibody to Vascular Endothelial Growth Factor: Does the Metastatic Site Make the Difference?. Journal of Clinical Oncology, 2003, 21, 3542-3543.	0.8	13
599	Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Annals of Oncology, 2003, 14, 205-208.	0.6	27
600	P-CHOP: Cisplatin (P) Added to the Standard CHOP Regimen as First-Line Treatment for Aggressive Non-Hodgkin Lymphoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2003, 26, 535-542.	0.6	1
601	Vascular Endothelial Growth Factor and p53 Expressions in Liver and Abdominal Metastases from Colon Cancer. Tumor Biology, 2003, 24, 77-81.	0.8	10
602	Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: A low cost effective regimen. British Journal of Cancer, 2002, 86, 213-217.	2.9	13
603	HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer. Annals of Oncology, 2002, 13, 1398-1403.	0.6	50
604	Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial. Journal of Clinical Oncology, 2002, 20, 3478-3483.	0.8	331
605	Thymidylate synthase protein expression in colorectalcancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. Annals of Oncology, 2002, 13, 1882-1892.	0.6	39
606	Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). Annals of Oncology, 2002, 13, 716-720.	0.6	45
607	Biological parameters on computed tomography guided fine needle aspiration biopsy from peripheral primary non-small cell lung cancer. Lung Cancer, 2002, 35, 243-247.	0.9	6
608	La Gestione Del Paziente Con Carcinoma Gastrico. Tumori, 2002, 1, S3-S10.	0.6	1
609	Influence of 5-Fluorouracil and Folinic Acid on Interleukin-18 Production in Colorectal Cancer Patients. International Journal of Biological Markers, 2002, 17, 63-66.	0.7	4
610	Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene, 2002, 21, 8192-8195.	2.6	91
611	An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation. British Journal of Cancer, 2002, 86, 744-749.	2.9	46
612	Influence of 5-fluorouracil and folinic acid on interleukin-18 production in colorectal cancer patients. International Journal of Biological Markers, 2002, 17, 63-66.	0.7	2

#	Article	IF	Citations
613	Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: Relationships with tumor recurrence and resistance to adjuvant chemotherapy. Annals of Oncology, 2001, 12, 239-244.	0.6	43
614	Gastrointestinal Cancer Refractory to Chemotherapy: A Role for Octreotide?. Chemotherapy, 2001, 47, 127-133.	0.8	9
615	Ipsilateral supraclavicular lymph nodes metastases from breast cancer as only site of disseminated disease. Chemotherapy alone vs. induction chemotherapy to radical radiation therapy. Annals of Oncology, 2001, 12, 1091-1095.	0.6	18
616	Molecular markers predictive of response to chemotherapy in gastrointestinal tumors. Critical Reviews in Oncology/Hematology, 2001, 38, 93-104.	2.0	17
617	Novel therapeutic approaches to cancer patients with bone metastasis. Critical Reviews in Oncology/Hematology, 2001, 40, 239-250.	2.0	36
618	Cutaneous seeding after ultrasound-guided percutaneous ethanol injection for treatment of hepatocellular carcinoma. Journal of Clinical Ultrasound, 2001, 29, 354-358.	0.4	18
619	A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer. British Journal of Cancer, 2001, 84, 470-474.	2.9	39
620	Potential role and chronology of abnormal expression of the Deleted in Colon Cancer (DCC) and the p53 proteins in the development of gastric cancer. BMC Cancer, 2001, 1, 9.	1.1	24
621	Nerve Growth Factor Receptor Immunoreactivity in Breast Cancer Patients. Cancer Investigation, 2001, 19, 692-697.	0.6	19
622	Inhibition of Vascular Endothelial Growth Factor by Octreotide in Colorectal Cancer Patients. Cancer Investigation, 2001, 19, 8-12.	0.6	45
623	Prognostic biomarkers in resected colorectal cancer: implications for adjuvant chemotherapy. Expert Review of Anticancer Therapy, 2001, 1, 247-257.	1.1	8
624	Survival and quality of life in gastrointestinal tumors: Two different end points?. Annals of Oncology, 2001, 12, S31-S36.	0.6	5
625	A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Annals of Oncology, 2000, 11, 1263-1266.	0.6	78
626	Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials. Annals of Oncology, 2000, 11, 837-843.	0.6	339
627	A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Annals of Oncology, 2000, 11, 1309-1312.	0.6	32
628	Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors. Clinical and Experimental Metastasis, 2000, 18, 651-655.	1.7	26
629	High-dose loperamide in the treatment of 5-fluorouracil-induced diarrhea in colorectal cancer patients. Supportive Care in Cancer, 2000, 8, 65-67.	1.0	25
630	Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracilâ€"leucovorin combination. Annals of Oncology, 2000, 11, 1053-1056.	0.6	18

#	Article	IF	Citations
631	Immunohistochemical telomeric-repeat binding factor-1 expression in gastrointestinal tumors.. Oncology Reports, 2000, 7, 987-90.	1.2	7
632	SPECIAL DEPARTMENTS. Journal of Clinical Oncology, 2000, 18, 445-445.	0.8	3
633	Effects of Calcium and Vitamin Supplementation on Colon Cell Proliferation in Colorectal Cancer. Cancer Investigation, 2000, 18, 411-416.	0.6	31
634	Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clinical Cancer Research, 2000, 6, 2803-7.	3.2	155
635	Angiosuppression and Chemotherapy: Strategies Aimed at Their Integration in Cancer Patients. International Journal of Biological Markers, 1999, 14, 239-242.	0.7	1
636	Chemotherapy for advanced pancreatic cancer: It may no longer be ignored. Annals of Oncology, 1999, 10, 105-110.	0.6	24
637	Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase II study. Annals of Oncology, 1999, 10, 217-222.	0.6	23
638	A phase Iâ€“II study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Annals of Oncology, 1999, 10, 1377-1379.	0.6	43
639	Resection-line Involvement in Gastric Cancer Patients Undergoing Curative Resections: Implications for Clinical Management. Japanese Journal of Clinical Oncology, 1999, 29, 291-293.	0.6	42
640	Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). British Journal of Cancer, 1999, 79, 491-494.	2.9	7
641	A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). British Journal of Cancer, 1999, 80, 1595-1598.	2.9	81
642	Thymidylate synthase (TS) protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil (5FU). European Journal of Cancer, 1999, 35, S70.	1.3	41
643	Oxaliplatin (L-OHP) in combination with leucovorin and bolus-continuous infusion 5fluorouracil (LV5FU2) in advanced colorectal cancer (ACC) pretreated with 5fu. European Journal of Cancer, 1999, 35, S80.	1.3	0
644	DCC and p53 protein expression in early stages of gastric cancer. European Journal of Cancer, 1999, 35, S192.	1.3	0
645	An evaluation of potential neuroprotective effect of reduced-glutathione (GSH) on oxaliplatin (OXA) based chemotherapy in advanced colorectal cancer patients. European Journal of Cancer, 1999, 35, S375-S376.	1.3	3
646	A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. Annals of Oncology, 1999, 10, 985-987.	0.6	5
647	Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clinical Cancer Research, 1999, 5, 1996-9.	3.2	80
648	Angiosuppression and chemotherapy: strategies aimed at their integration in cancer patients. International Journal of Biological Markers, 1999, 14, 239-42.	0.7	0

#	Article	IF	Citations
649	Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). British Journal of Cancer, 1998, 78, 390-393.	2.9	35
650	S-phase fraction can predict event free survival in patients with pT2-T3N0M0 colorectal carcinoma. Cancer, 1998, 83, 1081-1085.	2.0	16
651	Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer, 1998, 83, 1917-1922.	2.0	65
652	Different doses of pamidronate in patients with painful osteolytic bone metastases. Supportive Care in Cancer, 1998, 6, 139-143.	1.0	33
653	Locoregional treatments of unresectable liver metastases from colorectal cancer. Cancer Treatment Reviews, 1998, 24, 3-14.	3.4	12
654	Phase II study of paclitaxel in pretreated advanced gastric cancer. Anti-Cancer Drugs, 1998, 9, 307-310.	0.7	91
655	A Pilot Clinical Trial of Postoperative Intensive Weekly Chemotherapy Using Cisplatin, Epi-Doxorubicin, 5-Fluorouracil, 6S-Leucovorin, Glutathione and Filgrastim in Patients with Resected Gastric Cancer. Tumori, 1998, 84, 368-371.	0.6	3
656	Chemotherapy for Advanced Pancreatic Cancer: The History is Changing. Tumori, 1998, 84, 308-311.	0.6	5
657	Gemcitabine (GEM) and 5-fluorouracil (5 FU) in advanced pancreatic cancer: A GISCAD phase II study. European Journal of Cancer, 1997, 33, S280.	1.3	3
658	p53 Status as potential predictor for response to chemotherapy in locally advanced gastric cancer. European Journal of Cancer, 1997, 33, S276.	1.3	0
659	A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. European Journal of Cancer, 1997, 33, 1699-1702.	1.3	28
660	Inhibition of tumor cell kinetics and serum insulin growth factor I levels by octreotide in colorectal cancer patients. Gastroenterology, 1997, 113, 767-772.	0.6	28
661	Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer.. Journal of Clinical Oncology, 1997, 15, 3313-3319.	0.8	100
662	High- versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: A â€˜GISCADâ€™ phase III study. Annals of Oncology, 1997, 8, 169-174.	0.6	25
663	Delayed emesis induced by moderately emetogenic chemotherapy: Do we need to treat all patients?. Annals of Oncology, 1997, 8, 561-567.	0.6	22
664	Liver metastases from colorectal cancer. Annals of Oncology, 1997, 8, 393-399.	0.6	4
665	Evaluation of factors influencing 5-fluorouracil-induced diarrhea in colorectal cancer patients. Supportive Care in Cancer, 1997, 5, 314-317.	1.0	29
666	Tumor Markers in the Diagnosis of Malignant Serous Effusions. American Journal of Clinical Oncology: Cancer Clinical Trials, 1997, 20, 247-250.	0.6	38

#	Article	IF	Citations
667	The Clinical Impact of Teniposide in the Treatment of Elderly Patients with Small-Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1997, 20, 477-478.	0.6	20
668	Measurements of cellular proliferation by H-3-thymidine-labeling index and flow cytometry in breast cancer patients. Oncology Reports, 1997, 4, 539-41.	1.2	0
669	Chemo-embolization in the treatment of liver metastases from colorectal cancer. Cancer Treatment Reviews, 1996, 22, 355-363.	3.4	7
670	Different doses of granulocyte colony stimulating factor to support a weekly chemotherapeutic regimen in advanced gastric cancer. Anti-Cancer Drugs, 1996, 7, 43-47.	0.7	3
671	A phase I trial of 5-fluorouracil, leucovorin and interferon-Î±2b administered by 24 h infusion in metastatic colorectal carcinoma. Anti-Cancer Drugs, 1996, 7, 520-524.	0.7	3
672	Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy. Supportive Care in Cancer, 1996, 4, 31-33.	1.0	12
673	Multimodal biochemical modulation of 5-fluorouracil by leucovorin, methotrexate, and interferon alpha in patients with advanced colorectal cancer. Cancer Chemotherapy and Pharmacology, 1996, 38, 385-386.	1.1	4
674	S-phase fraction and tumor aneuploidy in colorectal carcinoma of young patients. , 1996, 78, 1857-1860.		9
675	A phase II randomised trial of 5-fluorouracil with or without interferon alpha-2a in advanced colorectal cancer. British Journal of Cancer, 1996, 74, 971-974.	2.9	9
676	Toxicity and Therapeutic Response to Chemotherapy in Patients Aged 70 Years or Older with Advanced Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1996, 19, 371-374.	0.6	45
677	c-erbB-2 and common prognostic factors in breast cancer patients. Oncology Reports, 1996, 3, 883-6.	1.2	0
678	Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial.. Journal of Clinical Oncology, 1995, 13, 26-32.	0.8	171
679	Escalating dose of tegafur combined with oral etoposide in metastatic gastric carcinoma. Anti-Cancer Drugs, 1995, 6, 608-611.	0.7	1
680	Have enteric infections a role in 5-fluorouracil-associated diarrhea?. Supportive Care in Cancer, 1995, 3, 322-323.	1.0	2
681	A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. British Journal of Cancer, 1995, 71, 97-101.	2.9	71
682	Drug therapy in diarrheal diseases in oncology/hematology patients. Critical Reviews in Oncology/Hematology, 1995, 18, 37-50.	2.0	9
683	Intensive Weekly Chemotherapy for Elderly Gastric Cancer Patients, Using 5-Fluorouracil, Cisplatin, Epi-Doxorubicin, 6S-Leucovorin and Glutathione with the Support of G-CSF. Tumori, 1995, 81, 32-35.	0.6	7
684	Recombinant Human Erythropoietin Treatment in Elderly Cancer Patients with Cisplatinâ€“Associated Anemia. Oncology, 1995, 52, 422-426.	0.9	32

#	Article	IF	Citations
685	Recombinant human erythropoietin in chemotherapy-associated anemia. Cancer Treatment Reviews, 1995, 21, 553-564.	3.4	2
686	WEEKLY 24-HOUR INFUSION WITH HIGH-DOSE 5-FLUOROURACIL AND 6S-LEUCOVORIN AS A 2ND-LINE THERAPY IN ADVANCED COLORECTAL-CANCER RESISTANT TO A 5-FLUOROURACIL/6S-LEUCOVORIN BOLUS COMBINATION. Oncology Reports, 1995, 2, 377-9.	1.2	0
687	ORAL ESCALATING DOSE OF CYCLOSPORINE-A COMBINED WITH 4-EPIDOXORUBICIN IN ADVANCED COLORECTAL-CANCER - A PHASE-I STUDY. Oncology Reports, 1995, 2, 1033-5.	1.2	0
688	Intensive weekly chemotherapy for elderly gastric cancer patients, using 5-fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin and glutathione with the support of G-CSF. Tumori, 1995, 81, 32-5.	0.6	5
689	Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer. British Journal of Cancer, 1994, 69, 392-393.	2.9	11
690	Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-Î±2b and folinic acid. The â€œGISCADâ€•experience. European Journal of Cancer, 1994, 30, 1611-1616.	1.3	7
691	Etoposide, leucovorin, 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients: a pilot study. Cancer Chemotherapy and Pharmacology, 1994, 34, 72-74.	1.1	7
692	Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. European Journal of Cancer Part B, Oral Oncology, 1994, 30, 234-236.	0.9	111
693	Control of Chemotherapy-Induced Diarrhea with Octreotide. Oncology, 1994, 51, 70-73.	0.9	39
694	Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo.. Journal of Clinical Oncology, 1994, 12, 1058-1062.	0.8	194
695	CORRELATION AMONG [H-3] THYMIDINE, FLOW-CYTOMETRY AND PROLIFERATING CELL NUCLEAR ANTIGEN INDEXES IN COLORECTAL TUMORS. Oncology Reports, 1994, 1, 1229-32.	1.2	1
696	Breast cancer developing after therapy for Hodgkin's disease. Clinical Oncology, 1993, 5, 61-62.	0.6	4
697	Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study. British Journal of Cancer, 1993, 67, 156-158.	2.9	28
698	INTENSIVE WEEKLY CHEMOTHERAPY FOR ADVANCED GASTRIC-CANCER USING 5-FLUOROURACIL, CISPLATIN, EPI-DOXORUBICIN, 6S-LEUCOVORIN AND GRANULOCYTE-COLONY-STIMULATING FACTOR. International Journal of Oncology, 1993, 3, 535-8.	1.4	2
699	5-Fluorouracil, leucovorin and interferon alpha 2b in advanced pancreatic cancer: A pilot study. Annals of Oncology, 1993, 4, 83-84.	0.6	19
700	Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial.. Journal of Clinical Oncology, 1993, 11, 148-151.	0.8	90
701	Control of chemotherapy-induced diarrhoea with octreotide in patients receiving 5-fluorouracil. European Journal of Cancer, 1992, 28, 482-483.	1.3	29
702	Double biochemical modulation of 5-fluorouracil by leucovorin and cyclic low dose interferon alpha 2b in advanced colorectal cancer patients. Annals of Oncology, 1992, 3, 489-491.	0.6	16

#	Article	IF	Citations
703	Gastric cancer treatment: a systematic review. Oncology Reports, 0, , .	1.2	10
704	Mutations in the p53 and Ki-ras genes, microsatellite instability and site of tumor origin in colorectal cancer. Oncology Reports, 0, , .	1.2	5
705	CARBOPLATIN ASSOCIATED ANEMIA TREATED WITH SUBCUTANEOUS ERYTHROPOIETIN - A PILOT-STUDY. Oncology Reports, 0, , .	1.2	3